Project Description

Biotechnology

Branch:

Günter Steffen

ZFHN Partner:

2006

Initial investment:

Eleva develops drug candidates to advance into the clinic with pharmaceutical partners.

Dr. Andreas Schaaf

Chief Executive

Biotechnology

Branch:

Günter Steffen

ZFHN Partner:

2006

Initial investment:

Eleva develops drug candidates to advance into the clinic with pharmaceutical partners.

Dr. Andreas Schaaf

Chief Executive

Home-Portfolio-Eleva GmbH

Eleva is a biopharmaceutical company.

The company based in Freiburg leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins.

Eleva has successfully developed drug candidates into clinical phases and continues to scout for promising compounds.

“

Unlocking novel therapies is our mission. It becomes possible through the patience and the continuity of our long-standing investor and partner, the ZFHN.

Dr. Andreas Schaaf

CEO

“

Unlocking novel therapies is our mission. It becomes possible through the patience and the continuity of our long-standing investor and partner, the ZFHN.

Dr. Andreas Schaaf

CEO

2020
Rebranding of Greenovation as eleva GmbH
2019
Scale-up to 500 L Bioreactors
2017
Greenovation Biotech GmbH successfully completes the clinical stage-I study of mossaGal for the treatment of Fabry disease.
2015
The German Federal Institute for Drugs and Devices gives its approval to Greenovation to begin a phase-I clinical trial in Europe for moss-aGal (agalsidase), the first-ever drug produced in moss worldwide.
2014
First-ever production of a GMP-compliant drug substance manufactured in moss for clinical use.
2012
moss-aGal enters into preclinical phase
2006
ZFHN invests in Greenovation. Following investments by LEA Eigenkapital AG and other parties in Greenovation in 2002, from this point on, ZFHN is responsible for the financing and the further development of the company.
2003
First patent granted moss-bioreactor EP1206561
1999
Founding of Greenovation Pflanzenbiotechnologie, by Prof. Dr. Gunther Neuhaus and Prof. Dr. Ralf Reski (both of the Albert Ludwigs University in Freiburg)